Immunology
3 drugs are in development for Relapsing Multiple Sclerosis.
- Companies
- 2
- Clinical trials
- 20
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Relapsing Multiple Sclerosis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Remibrutinib | Novartis AG (NVS) |
Phase 4(2)
About this indication
Relapsing Multiple Sclerosis context
Immunology·MeSH: Multiple Sclerosis (D009103)
Narrower concept of MeSH descriptor Multiple Sclerosis
Prevalence
120.0 / 100K
Incidence
7.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsing Multiple Sclerosis?
BioSniper tracks 3 drugs in development for Relapsing Multiple Sclerosis across 2 companies.
How many clinical trials target Relapsing Multiple Sclerosis?
There are 20 clinical trials targeting Relapsing Multiple Sclerosis tracked by BioSniper.
What is the prevalence of Relapsing Multiple Sclerosis?
The estimated prevalence of Relapsing Multiple Sclerosis is approximately 120.0 per 100,000 population.